Pomerantz LLP is investigating claims on behalf of investors of NovoCure Limited regarding potential securities fraud or unlawful business practices. The investigation follows NovoCure's June 18, 2026 announcement that its Phase 3 TRIDENT trial did not show a statistically significant improvement in overall survival for the early start of Tumor Treating Fields therapy compared to the maintenance start arm. On that news, NovoCure's stock price fell $3.57 per share, or 20%, to close at $14.28 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
Novocure LtdPhase 3 trial failed to show statistically significant improvement, causing 20% stock drop.